Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol
- PMID: 2899439
- PMCID: PMC1276876
- DOI: 10.1136/hrt.59.6.685
Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol
Abstract
Celiprolol (400 mg) and atenolol (100 mg) were given once a day to 16 patients with stable angina pectoris in a double blind placebo controlled crossover study. Celiprolol produced less suppression of heart rate both at rest and during exercise than atenolol. Both drugs were equally effective in reducing the frequency of angina and in delaying the onset of ischaemia during exercise. Radionuclide ventriculography showed that atenolol but not celiprolol lowered cardiac output at rest and during exercise. Thus the ancillary properties of celiprolol, including partial beta 2 agonist activity and direct vasodilating activity, have detectable effects on cardiac function that may be beneficial in patients with angina.
Similar articles
-
Celiprolol and atenolol in angina--effects on left ventricular function.J Int Med Res. 1988;16 Suppl 1:47A-51A. J Int Med Res. 1988. PMID: 2906017 Clinical Trial.
-
Atenolol and celiprolol for stable angina pectoris.Am J Cardiol. 1988 Feb 10;61(5):52C. doi: 10.1016/0002-9149(88)90486-9. Am J Cardiol. 1988. PMID: 2893533 Clinical Trial.
-
Angina, ischemia, and effort tolerance with vasodilating beta-blockers.Am Heart J. 1991 Mar;121(3 Pt 2):1017-20. doi: 10.1016/0002-8703(91)90614-n. Am Heart J. 1991. PMID: 1671726 Clinical Trial.
-
Celiprolol in angina pectoris.Am Heart J. 1988 Nov;116(5 Pt 2):1422-5. doi: 10.1016/0002-8703(88)90134-2. Am Heart J. 1988. PMID: 2903653 Review.
-
Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.Drugs. 1987 Oct;34(4):438-58. doi: 10.2165/00003495-198734040-00002. Drugs. 1987. PMID: 2890513 Review.
Cited by
-
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.Drugs Aging. 1995 Nov;7(5):394-411. doi: 10.2165/00002512-199507050-00006. Drugs Aging. 1995. PMID: 8573993 Review.
-
A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.Drug Saf. 1994 Mar;10(3):220-32. doi: 10.2165/00002018-199410030-00004. Drug Saf. 1994. PMID: 7913813 Review.
-
Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.Drugs. 1991 Jun;41(6):941-69. doi: 10.2165/00003495-199141060-00009. Drugs. 1991. PMID: 1715268 Review.
-
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.Drugs. 1991 Sep;42(3):468-510. doi: 10.2165/00003495-199142030-00007. Drugs. 1991. PMID: 1720383 Review.
-
Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.Cardiovasc Drugs Ther. 1995 Feb;9(1):133-9. doi: 10.1007/BF00877753. Cardiovasc Drugs Ther. 1995. PMID: 7786833 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical